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Background
Graft-Versus-Host-Disease (GVHD) is a life-threatening complication 
of allogeneic hematopoietic stem cell transplantation (HSCT). 
Animal models have demonstrated that Treg infusion could prevent 
otherwise lethal GVHD in mice given grafts from MHC-disparate 
donors. Here, we assessed the ability of clinical-grade isolated 
human Treg to attenuate experimental xenogeneic GVHD.
Material and methods
Human Treg were isolated from cytapheresis products with the 
Miltenyi CliniMacs system using a two steps procedure (CD8 and 
CD19 depletion followed by CD25 positive selection) in six 
independent experiments with six different healthy volunteer 
donors. Sub-lethally (2.5 Gy) irradiated NSG mice were given 2x106 
cytapheresis product cells i.v. without (PBMC group) or with 1x106 
Tregs (PBMC+Treg group), while other NSG mice received only 
2x106 Treg (also in i.v.; Treg group). Mice in terminal stage GVHD 
were euthanised.
Results
After the selection, we obtained a CD25 enriched fraction including 
a median of 1.81 x108 cells and containing 59 +/- 6% or 66 +/- 6% 
Treg defined as either CD45+CD4+CD25HighFoxP3+ cells or CD45+CD4+ 
CD25highCD127low cells. In all experiments but the last (a technical 
problem dramatically impacts the efficiency of this selection), Treg 
co-transfusion significantly delayed death from xenogeneic GVHD. 
Specifically, median survivals in PBMC versus PBMC+Treg mice were 
30 vs 56 days (p=0.015), 123.5 vs >162 days (p=0.23), 25.5 vs 70 days 
(p=0.012), 13 vs 16 days (p=0.038), 27 vs 49 days (p=0.061), and 46 
vs 47 days (p=0.338) respectively. Further, none of the mice given 
only Treg experienced signs of GVHD, while, interestingly, the CD4+ 
cells found in these mice 27 days after transplantation were mainly 
conventional T cells (CD25+FoxP3+ cells in human CD4+ total cells 
were only 2.1%, 3.1% and 17.7% in spleen, bone marrow and 
blood, respectively while 80.2% were grafted).
Conclusion
Treg infusion delayed the occurrence of xenogeneic GVHD without 
showing any toxicity in this murine model.
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Based on the impairment of erythropoietin production after allo-
geneic hematopoietic cell transplantation (HCT), we previously 
reported in a phase-2 trial that recombinant human erythropoietin 
(rhEPO) therapy was very efficient when started one month after 
transplantation. We also demonstrated that anemia after non-
myeloabalative (NM) HCT was less sensitive to rhEPO therapy than 
after conventional allogeneic HCT. This prompted us to confirm 
these findings in a prospective randomised trial.
One hundred and thirty-one patients were randomised (1:1) between 
no treatment (arm 1) or erythropoietin (Neorecormon) at the dose 
of 500 U/kg/week (arm 2). Once the target Hb (13g/dL) has been 
attained, the dose of rhEPO was reduced by half, while it was 
withheld when Hb was = 14g/dL. Cohort A included 42 patients on 
day 28 after myeloablative HCT, cohort B 39 patients on day 28 
after NMHCT, and cohort C 50 patients on day 0 of NMHCT. Primary 
endpoints included proportion of complete correctors (i.e. patients 
reaching Hb = 13g/dL) and median time to achieve Hb correction in 
each arm.
The proportion of complete correctors before day 126 post-
transplant was 0% in group 1A vs 52.4% in group 2A, 0% in group 
1B vs 69.5% in group 2B and 19.1% in group 1C vs 70.2% in group 
2C. Median time to achieve Hb = 13g/dL was not reached in group 
1B vs 49 days in group 2B; 363 and 59 days in groups 1A and 1B 
respectively and 363 and 87 days in groups 3A and 3B respectively 
(figure 1). Hb evolution in each group is shown in figure 2. Seventy-
one patients (47/62 in control groups and 24/57 in treated groups, 
p=0.0003) required red blood cell transfusions. The difference was 
most pronounced in cohort B. There was no difference in rates of 
thrombo-embolic events or other complications between the two 
arms. In conclusion, this is the first trial to demonstrate that EPO 
therapy hastens erythroid recovery and decreases transfusion 
requirements when started one month after allogeneic HCT.
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Asparaginase (ASP) is an essential component in combination chemo-
therapy for childhood ALL. However, the optimal number of ASP-
administrations is still unknown. We conducted a randomised 
phase III trial comparing conventional E.coli-ASP-regimen (short-ASP, 
12 doses) with prolonged E.coli-ASP-therapy (long-ASP, 24 doses).
Methods
The EORTC-CLG 58951 trial was open to de novo ALL or NHL 
patients (pts) <18y. This study addressed two main randomised 
questions. The first evaluated the value of dexamethasone (DEX, 
6mg/m/d) vs prednisolone (PRED, 60mg/m/d) in induction for all 
patients. In the second question all non-VHR pts were randomised 
for either short- or long-ASP. All patients received 8x10000U/m in 
induction. In the short-ASP-arm patients received 4x10000U/m in 
reinduction; patients in the long-ASP-arm received 8x5000U/m E.
coli-ASP-injections in consolidation and eight (4x10000U/m + 4x 
5000U/m) in reinduction. Patients with grade =2 allergy to E.coli-
ASP were switched to equivalent doses of Erwinia or PEG-ASP.
Results
Between 12/1998 and 08/2008, 1552 patients were randomly assigned 
to receive long-ASP (n=775) or short-ASP (n=777). The 8-year DFS rate 
was 87.0% in the long-ASP and 84.2% in short-ASP-group (hazard 
ratio (HR) = 0.87, 95% CI 0.66-1.14, 2-sided logrank p=0.30). The 8-year 
OS rate was comparable in both treatment arms: 92.6% in the long-
ASP-group and 91.3% in the short-ASP-group (HR = 0.89, 95% CI 0.61- 
1.29, p=0.53). Similar treatment differences were observed in each 
risk group, in PRED vs DEX arm, and B- and T-lineage ALL-patients.
The incidence of grade 3-4 infection was higher in the long- versus 
short-ASP-group during consolidation (25.2% vs 14.5%) and re-
induction (22.6% vs 15.9%). This difference was more pronounced 
in patients who received DEX in induction (27.3% vs 11.6%). During 
the whole treatment period, the incidence of grade 2-4 allergy was 
32.8% in the long-ASP-arm and 21.8% in the short-ASP-arm.
Conclusion
At long follow-up prolonged E.coli asparaginase therapy in conso-
